I can speak only to the research and innovation pillar and specifically only as it pertains to products' introduction to Canada and to the innovation cycle that happens in Canada. I'll stay within that space.
Part of the pan-Canadian action plan speaks to the need for push-and-pull incentives. Pull incentives are basically incentivizing companies to bring their products into Canada. As I mentioned, there are only three out of 18 that have come to Canada. There are two main reasons for that.
First of all, relatively speaking, Canada is a smaller market. It's the size of California. To bring a product into Canada, with such a large geographical size, is complicated. More important than that are the silos that exist between federal, provincial and territorial jurisdictions. A drug cannot enter into the hospital setting without having to go through that cycle.
When we introduced the pan-Canadian action plan 2023, we insisted on the fact that there had to be complete transparency and open discussion between the different federal levels. What has become apparent is that there's also that division at the departmental levels you talked about. For example, I sit on the Public Health Agency's external advisory group on AMR. The action plan is a five-year action plan, and two years have already gone. We're into the third year right now, and we're saying that there is—
I'm sorry. Go ahead.